AU7786387A - Composition of matter and method of immunizing against viral causative agents of aids and arc - Google Patents

Composition of matter and method of immunizing against viral causative agents of aids and arc

Info

Publication number
AU7786387A
AU7786387A AU77863/87A AU7786387A AU7786387A AU 7786387 A AU7786387 A AU 7786387A AU 77863/87 A AU77863/87 A AU 77863/87A AU 7786387 A AU7786387 A AU 7786387A AU 7786387 A AU7786387 A AU 7786387A
Authority
AU
Australia
Prior art keywords
aids
arc
matter
composition
against viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU77863/87A
Inventor
Patrick Kanda
Ronald C. Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas Biomedical Research Institute
Original Assignee
Texas Biomedical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biomedical Research Institute filed Critical Texas Biomedical Research Institute
Publication of AU7786387A publication Critical patent/AU7786387A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU77863/87A 1986-07-21 1987-07-20 Composition of matter and method of immunizing against viral causative agents of aids and arc Abandoned AU7786387A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88874286A 1986-07-21 1986-07-21
US888742 1992-05-22

Publications (1)

Publication Number Publication Date
AU7786387A true AU7786387A (en) 1988-02-10

Family

ID=25393799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77863/87A Abandoned AU7786387A (en) 1986-07-21 1987-07-20 Composition of matter and method of immunizing against viral causative agents of aids and arc

Country Status (5)

Country Link
EP (1) EP0276279A4 (en)
JP (1) JPH01500432A (en)
AU (1) AU7786387A (en)
DK (1) DK149188A (en)
WO (1) WO1988000471A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU635217B2 (en) * 1988-08-27 1993-03-18 Akzo N.V. Synthetic peptides immunochemically reactive with hiv-antibodies
AU640615B2 (en) * 1988-08-26 1993-09-02 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv-antibodies

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
EP0255190A3 (en) * 1986-08-01 1990-08-29 Repligen Corporation Recombinant polypeptides and their uses, inclusing assay for aids virus
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
KR900701836A (en) * 1988-10-03 1990-12-04 라메쉬 엘. 라탄 Peptides useful for diagnosing, preventing or treating new HIV proteins and AIDS
IL94558A0 (en) * 1989-06-06 1991-03-10 Merck & Co Inc Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
EP0448095A1 (en) * 1990-03-21 1991-09-25 Wolf, Hans Joachim, Prof. Dr. Subregion of the retroviral ENV protein, DNA sequences encoding it and compositions for the diagnosis, prevention or therapy of retrovirus infections
CA2047073A1 (en) * 1990-07-19 1992-01-20 William J. Leanza Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
FR2677654B1 (en) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc COMPOUNDS WITH AN IMMUNOGENIC ANTI-CYTOKIN EFFECT, AN ANTIYTOSTATIC IMMUNOGENIC EFFECT OR AN ANTI-HIV INFECTION VACCINE EFFECT.
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
DE4417742A1 (en) 1994-05-20 1995-11-23 Bayer Ag Non-systemic control of parasites
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
DE69938062T2 (en) 1998-12-31 2009-01-15 Novartis Vaccines and Diagnostics, Inc., Emeryville MODIFIED HIV ENV POLYPEPTIDE
EP1141313A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6659681B1 (en) 1999-02-10 2003-12-09 Traf Fix Devices, Inc. Laterally stable vertical panel system
JP5033303B2 (en) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Polynucleotides encoding polypeptides with antigenic type C HIV, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1427806A4 (en) 2001-08-31 2006-04-26 Chiron Corp Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
CN106257728B (en) 2016-01-28 2018-01-12 中国科学院过程工程研究所 A kind of system and method for producing the high-purity V electrolyte of 3.5 valencys

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
JP2702911B2 (en) * 1985-09-11 1998-01-26 ユナイテツド・バイオメデイカル・インコ−ポレ−テツド Synthetic peptide, and method for detecting AIDS and pre-AIDS using the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640615B2 (en) * 1988-08-26 1993-09-02 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv-antibodies
AU635217B2 (en) * 1988-08-27 1993-03-18 Akzo N.V. Synthetic peptides immunochemically reactive with hiv-antibodies

Also Published As

Publication number Publication date
DK149188D0 (en) 1988-03-18
EP0276279A1 (en) 1988-08-03
EP0276279A4 (en) 1990-01-08
DK149188A (en) 1988-05-06
JPH01500432A (en) 1989-02-16
WO1988000471A1 (en) 1988-01-28

Similar Documents

Publication Publication Date Title
AU7786387A (en) Composition of matter and method of immunizing against viral causative agents of aids and arc
AU4205789A (en) Method and composition for the treatment and prevention of viral infections
AU564694B2 (en) Blends of polyetherimide and organosiloxane-polycarbonate block copolymers
AU559545B2 (en) Composition and method for treatment of glaucoma
AU7211787A (en) Intraocular dosage compositions and method of use
AU1550983A (en) Blends of polyetherimide and organosiloxane-polycarbonate block copolymers
AU1952288A (en) Method of selectively inhibiting hiv
AU8367991A (en) Method of purifying bisphenol-a
AU6110990A (en) Use of viruses against undesirable micro-organisms
AU5064985A (en) Methods and compositions for treating viral infection
AU6979487A (en) Treatment of gases
AU2855589A (en) Method and composition for accelerating the hardening of cements and removing efflorescent effects
AU3413389A (en) Method of treating retrovirus infection
AU5568290A (en) Method of suppressing hiv infection
AU6796287A (en) Method and composition for prophylaxis and treatment of viral infections
AU7515287A (en) Methods and compositions for treating viral infections
AU582303B2 (en) Method of curve approximation
AU6660090A (en) Treatment of depression
ZA87470B (en) Method and composition for prophylaxis and treatment of viral infections
AU7120987A (en) Composition for and method of treating aids and certain related diseases
AU5314886A (en) Method of detaching micro-flora and compositions therefor
AU628643B2 (en) Strain of myxococcus
AU4829190A (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
OA09507A (en) Compositions and methods for treating or preventing AIDS ARC and HIV infection
AU7360387A (en) Bacteriocins used for anti-viral treatment (particularly aids)